Drug Trial Radar · NCT07863180
Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Prabesh KanelAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Farmer Family Foundation
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.
Conditions
- Parkinson Disease
- Multiple System Atrophy
- Progressive Supranuclear Palsy(PSP)
Interventions
TributyrinDrug
Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.
PlaceboDrug
Participants will take 500mg TID placebo for 90 days +/- 7 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tolerability of tributyrinTime frame: Visit 7 (approximately day 90)
- Safety of tributyrinTime frame: Up to visit 7 (approximately day 90)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Domino's Farms
Ann Arbor, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.